# US 2025/0049725 A1 · Two-stage microparticle-based therapeutic delivery system and method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049725 A1
- Document ID: US20250049725A1
- Status: Published application
- Kind: A1
- Application number: 18/782,685
- Filed: 2024-07-24
- Published: 2025-02-13
- Earliest claimed: 2016-02-18
- Assignees: Privo Technologies, Inc.
- Applicants: Privo Technologies, Inc.
- Inventors: Manijeh Nazari Goldberg; Aaron Manzi; Brandon LaPorte; Amritpreet Birdi
- Web page: https://patentgrep.com/patent/US20250049725A1

## CPC

- A61K 9/5036: {Polysaccharides, e.g. gums, alginate; Cyclodextrin}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 31/282: Platinum compounds
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A system for delivery of a therapeutic agent to a site in mucosal tissue is provided. The system includes a porous, mucoadhesive polymeric matrix having a first and a second opposed surfaces. The matrix is formed by a composition including chitosan. The composition may also include any or all of a hydration promotor, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor. A plurality of microparticles having an average diameter between 500 nm and 2000 nm are embedded within the matrix. The microparticles contain a therapeutic agent and have a coating around the therapeutic agent. The first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles through the first surface. The coating of the microparticles includes chitosan so as to provide controlled release of the agent from the microparticles.

## Claims

### Claim 1

A system for delivery of a therapeutic agent to a site in mucosal tissue, the system comprising:
a porous, mucoadhesive, freeze-dried polymeric matrix, having first and second opposed surfaces, the matrix formed by a composition including chitosan and a plurality of microparticles, having an average diameter between 500 nm and 2000 nm, embedded within the matrix, the microparticles containing a therapeutic agent and having a coating around the therapeutic agent,
wherein:
(i) the first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles, through the first surface, when the first surface of the matrix is thus attached to the site; and
(ii) the coating includes chitosan so as to provide controlled release of the agent from the microparticles.

### Claim 2 (depends on 1)

A system according to claim 1, wherein the composition further includes a compound selected from a group consisting of a hydration promoter, a microparticle adhesion inhibitor comprising HPMC, a microparticle aggregation inhibitor, and combinations thereof.

### Claim 3 (depends on 2)

A system according to claim 2, wherein the hydration promoter is selected from the group consisting of ethylene glycol, propylene glycol, beta-propylene glycol, glycerol and combinations thereof.

### Claim 4 (depends on 2)

A system according to claim 2, wherein the microparticle aggregation inhibitor is selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, chlorinated monosaccharides, chlorinated disaccharides, and combinations thereof.

### Claim 5 (depends on 1)

A system according to claim 1, wherein the microparticles further include sodium tripolyphosphate.

### Claim 6 (depends on 1)

A system according to claim 1, further comprising a free amount of the therapeutic agent, embedded directly in the matrix, and not otherwise coated with chitosan, wherein the free amount of the therapeutic agent constitutes between 20-80% of a total amount of the therapeutic agent in the system.

### Claim 7 (depends on 1)

A system according to claim 1, wherein the second surface is permeable to water.

### Claim 8 (depends on 1)

A system according to claim 1, wherein the second surface includes a material selected from the group consisting of a polyacrylate adhesive, a non-woven polyester fabric, and combinations thereof.

### Claim 9 (depends on 1)

A system according to claim 1, wherein the chitosan in the matrix and the chitosan in the microparticles is pure chitosan.

### Claim 10 (depends on 1)

A system according to claim 1, wherein the therapeutic agent is a chemotherapeutic pharmaceutical.

### Claim 11 (depends on 1)

A system according to claim 1, wherein the chitosan of the microparticles is pure chitosan.

### Claim 12

A method for manufacturing a therapeutic agent delivery system, the method comprising:
forming a first mixture comprising a plurality of microparticles, the microparticles having an average diameter between 500 nm and 2000 nm, containing a therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan;
forming a second mixture from ingredients including the first mixture and chitosan;
freezing the second mixture in a bath containing an aqueous alcoholic solution at a temperature above the freezing temperature of the aqueous alcoholic solution and at most −40° C., to form a frozen layer precursor; and
drying the frozen layer precursor, to form a porous polymeric matrix with microparticles embedded within the matrix.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the second mixture further includes a compound selected from the group consisting of a hydration promoter, a microparticle adhesion inhibitor comprising HPMC, a microparticle aggregation inhibitor, and combinations thereof.

### Claim 14 (depends on 12)

A method according to claim 12, further comprising embedding a free quantity of the therapeutic agent directly in the matrix, wherein the free quantity of the therapeutic agent constitutes between about 20-80% of a total quantity of therapeutic agent in the system.

### Claim 15 (depends on 12)

A method according to claim 12, further comprising applying a second layer precursor to the frozen layer precursor, to form a solid comprising a first layer and a second layer.

### Claim 16 (depends on 14)

A method according to claim 14, wherein the second layer comprises a therapeutic agent.

### Claim 17 (depends on 12)

A method according to claim 12, further comprising coating the frozen layer precursor with a frozen second layer precursor, to form a solid comprising a first layer and a second layer.

### Claim 18 (depends on 13)

A method according to claim 13, wherein the hydration promoter is selected from the group consisting of ethylene glycol, propylene glycol, beta-propylene glycol, glycerol, and combinations thereof.

### Claim 19 (depends on 13)

A method according to claim 13, wherein the microparticle aggregation inhibitor is selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, chlorinated monosaccharides, chlorinated disaccharides, and combinations thereof.

### Claim 20 (depends on 12)

A method according to claim 12, wherein the therapeutic agent is a chemotherapeutic pharmaceutical.
